Categories
News on Health & Science

Waking up Dormant HIV

World HIV/AIDS Awareness Day
Image by reflexblue via Flickr

HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains dormant in cells. But, a chemical called suberoylanilide hydroxamic acid (SAHA), recently approved as a leukemia drug, has now been shown to ‘turn on’ latent HIV, making it an attractive candidate to weed out the hidden virus that HAART misses.
CLICK & SEE
Matija Peterlin at UCSF and colleagues had previously identified another chemical called HMBA that could activate latent HIV, but the risk of several toxic side effects made HMBA clinically non-viable. However, the chemically similar SAHA had received FDA approval, making it a potentially safer alternate.

So, the researchers examined whether SAHA had any effect on HIV latency. They found that SAHA could indeed stimulate latent HIV to begin replicating, which exposes the infected cell to HAART drugs. SAHA could activate HIV in both laboratory cells as well as from blood samples taken from HIV patients on antiretroviral therapy. Importantly, this successful activation was achieved using clinical doses of SAHA, suggesting toxicity will not be a problem.

Sources
:http://www.asbmb.org/News.aspx?id=2286

Categories
News on Health & Science

AIDS Can be Eliminated in 10 Years

The virus that causes AIDS could theoretically be eliminated in a decade if all people living in countries with high infection rates are regularly tested and treated, according to a new mathematical model………..CLICK & SEE

It is an intriguing solution to end the AIDS epidemic. But it is based on assumptions rather than data, and is riddled with logistical problems. The research was published online on Tuesday in the medical journal, the Lancet.

“It’s quite a startling result,” said Charlie Gilks, an AIDS treatment expert at the World Health Organization and one of the paper’s authors. “In a relatively short amount of time, we could potentially knock the epidemic on its head.”

Gilks and colleagues used data from South Africa and Malawi. In their model, people were voluntarily tested each year and immediately given drugs if they tested positive for HIV, regardless of whether they were sick. Within 10 years, HIV infections dropped by 95%. Other initiatives like safe sex education and male circumcision were also used.

The strategy would cut the estimated number of AIDS deaths between 2008 and 2050 by about half, from about 8.7 million to 3.9 million, leaving only sporadic HIV cases. Experts think the strategy’s cost would peak at about $3.4 billion a year, though expenses would fall after an initial investment.

“This is certainly beyond the bounds of the current infrastructure for many countries, but that is not a reason not to think big,” said Myron Cohen, of the University of North Carolina, who has done similar research.

Only 3 million people are currently on AIDS drugs. Nearly 7 million people are still awaiting treatment, and about 3 million more people were infected last year. Worldwide, WHO guesses that about 33 million people have HIV. Increasing access to testing and drugs would stretch already weak health systems in Africa, which has most of the world’s HIV cases.

WHO emphasized that the study findings do not signal a policy change. “This is only a theoretical exercise,” said Kevin De Cock, director of WHO’s HIV/AIDS department. He said WHO would hold a meeting next year to study the idea more closely.

Sources: The Times Of India

Reblog this post [with Zemanta]
Categories
News on Health & Science

Bone Marrow ‘Cures AIDS Patient’

[amazon_link asins=’1107661544,B06ZZPYQPT,1541905253,1118416007,0964735237,1511567953,B072M9QHGF,B00WEQTCUM,0521829127′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’05d36333-61f9-11e7-9b53-25a7c75de281′]

A bone marrow transplant using stem cells from a donor with natural genetic resistance to the AIDS virus has left an HIV patient free of infection for nearly two years, German researchers.

CLICK & SEE

The patient, an American living in Berlin, was infected with the human immunodeficiency virus that causes AIDS and also had leukemia.

The best treatment for the leukemia was a bone marrow transplant, which takes the stem cells from a healthy donor’s immune system to replace the patient’s cancer-ridden cells.

Dr Gero Hutter and Thomas Schneider of the Clinic for Gastroenterology, Infections and Rheumatology of the Berlin Charite hospital said on Wednesday the team sought a bone marrow donor who had a genetic mutation known to help the body resist AIDS infection.

The mutation affects a receptor, a cellular doorway, called CCR5 that the AIDS virus uses to get into the cells it infects.

When they found a donor with the mutation, they used that bone marrow to treat the patient. Not only did the leukemia disappear, but so did the HIV.

“As of today, more than 20 months after the successful transplant, no HIV can be detected in the patient,” the clinic said in a statement. “We performed all tests, not only with blood but also with other reservoirs,” Schneider told a news conference. “But we cannot exclude the possibility that it’s still there.”

The researchers stressed that this would never become a standard treatment for HIV. Bone marrow stem cell transplants are rigorous and dangerous and require the patient to first have his or her own bone marrow completely destroyed.

Patients risk death from even the most minor infections because they have no immune system until the stem cells can grow and replace their own.

HIV has no cure and is always fatal. Cocktails of drugs can keep the virus suppressed, sometimes to undetectable levels. But research shows the virus never disappears — it lurks in so-called reservoirs throughout the body.

Hutter’s team said they have been unable to find any trace of the virus in their 42-year-old patient, who remains unnamed, but that does not mean it is not there. “The virus is tricky. It can always return,” Hutter said.

The CCR5 mutation is found in about 3% of Europeans, the researchers said. They said the study suggests that gene therapy, a highly experimental technology, might someday be used to help treat patients with HIV.

Sources: The Times Of India

Reblog this post [with Zemanta]
Categories
Ailmemts & Remedies

Chlamydia-a Common Sexually Transmitted Disease (STD)

Definition:Chlamydia is a common sexually transmitted disease (STD) caused by the bacterium, Chlamydia trachomatis, which can damage a woman’s reproductive organs. Even though symptoms of chlamydia are usually mild or absent, serious complications that cause irreversible damage, including infertility, can occur “silently” before a woman ever recognizes a problem. Chlamydia also can cause discharge from the penis of an infected man.

CLICK & SEE

It is one of the most common bacterial sexually transmitted infections. 1 in 10 sexually active people tested have chlamydia, many do not know they have it. Having a simple test can tell you, if you have it.
Men and women can carry the infection. It is easily treated with antibiotics.

What can Chlamydia do to you?
Women: Chlamydia can spread to other reproductive organs causing pelvic inflammatory disease (PID). This can lead to long term pelvic pain, blocked fallopian tubes, infertility and ectopic pregnancy (pregnancy that can develop outside the womb).

 

Men: Chlamydia can lead to painful infection in the testicles and possibly reduced fertility. It is thought that in some men it might cause the prostrate to become inflamed.

Men and Women: Inflammation or swelling to the joints can occur (reactive ARTHRITIS). This is sometimes accompanied by inflammation of the urethra (the tube from the bladder to the outside of the body) ad the eye, when it is known as Reiter’s syndrome. This is rare and occurs more in men than in women.

Chlamydia is the most frequently reported bacterial sexually transmitted disease in the United States. In 2006, 1,030,911 chlamydial infections were reported to CDC from 50 states and the District of Columbia. Under-reporting is substantial because most people with chlamydia are not aware of their infections and do not seek testing. Also, testing is not often done if patients are treated for their symptoms. An estimated 2,291,000 non-institutionalized U.S. civilians ages 14-39 are infected with Chlamydia based on the U.S. National Health and Nutrition Examination Survey. Women are frequently re-infected if their sex partners are not treated.

Causes::Chlamydia can be transmitted during vaginal, anal, or oral sex. Chlamydia can also be passed from an infected mother to her baby during vaginal childbirth.

Any sexually active person can be infected with chlamydia. The greater the number of sex partners, the greater the risk of infection. Because the cervix (opening to the uterus) of teenage girls and young women is not fully matured and is probably more susceptible to infection, they are at particularly high risk for infection if sexually active. Since chlamydia can be transmitted by oral or anal sex, men who have sex with men are also at risk for chlamydial infection.

Symptoms: Chlamydia is known as a “silent” disease because about three quarters of infected women and about half of infected men have no symptoms. If symptoms do occur, they usually appear within 1 to 3 weeks after exposure.

In women, the bacteria initially infect the cervix and the urethra (urine canal). Women who have symptoms might have an abnormal vaginal discharge or a burning sensation when urinating. When the infection spreads from the cervix to the fallopian tubes (tubes that carry fertilized eggs from the ovaries to the uterus), some women still have no signs or symptoms; others have lower abdominal pain, low back pain, nausea, fever, pain during intercourse, or bleeding between menstrual periods.

Chlamydial infection of the cervix can spread to the rectum.

Men with signs or symptoms might have a discharge from their penis or a burning sensation when urinating. Men might also have burning and itching around the opening of the penis. Pain and swelling in the testicles are uncommon.

Men or women who have receptive anal intercourse may acquire chlamydial infection in the rectum, which can cause rectal pain, discharge, or bleeding. Chlamydia can also be found in the throats of women and men having oral sex with an infected partner.

Complications:If untreated, chlamydial infections can progress to serious reproductive and other health problems with both short-term and long-term consequences. Like the disease itself, the damage that chlamydia causes is often “silent.”

In women, untreated infection can spread into the uterus or fallopian tubes and cause pelvic inflammatory disease (PID). This happens in up to 40 percent of women with untreated chlamydia. PID can cause permanent damage to the fallopian tubes, uterus, and surrounding tissues. The damage can lead to chronic pelvic pain, infertility, and potentially fatal ectopic pregnancy (pregnancy outside the uterus). Women infected with chlamydia are up to five times more likely to become infected with HIV, if exposed.

To help prevent the serious consequences of chlamydia, screening at least annually for chlamydia is recommended for all sexually active women age 25 years and younger. An annual screening test also is recommended for older women with risk factors for chlamydia (a new sex partner or multiple sex partners). All pregnant women should have a screening test for chlamydia.

Complications among men are rare. Infection sometimes spreads to the epididymis (the tube that carries sperm from the testis), causing pain, fever, and, rarely, sterility.

Rarely, genital chlamydial infection can cause arthritis that can be accompanied by skin lesions and inflammation of the eye and urethra (Reiter’s syndrome).In pregnant women, there is some evidence that untreated chlamydial infections can lead to premature delivery. Babies who are born to infected mothers can get chlamydial infections in their eyes and respiratory tracts. Chlamydia is a leading cause of early infant pneumonia and conjunctivitis (pink eye) in newborns.

Diagnosis:
There are laboratory tests to diagnose chlamydia. Some can be performed on urine, other tests require that a specimen be collected from a site such as the penis or cervix.

Treatment:Chlamydia can be easily treated and cured with antibiotics. A single dose of azithromycin or a week of doxycycline (twice daily) are the most commonly used treatments. HIV-positive persons with chlamydia should receive the same treatment as those who are HIV negative.

All sex partners should be evaluated, tested, and treated. Persons with chlamydia should abstain from sexual intercourse until they and their sex partners have completed treatment, otherwise re-infection is possible.

Women whose sex partners have not been appropriately treated are at high risk for re-infection. Having multiple infections increases a woman’s risk of serious reproductive health complications, including infertility. Retesting should be encouraged for women three to four months after treatment. This is especially true if a woman does not know if her sex partner received treatment.

Herbal Treatment: YOU can fight infection causing inflammation of the genitals, vaginal or urethral discharge, difficulty urinating, painful intercourse, itching, or prostatitis with these herbs from Mother Nature’s medicine chest:

Astragalus, red clover, echinacea extract, goldenseal extract.

Quik Tip:
Red clover is a deeply nutritive herb with positive implications in the treatment of hormonal difficulties, infections and even cancer.

Prevention: The surest way to avoid transmission of STDs is to abstain from sexual contact, or to be in a long-term mutually monogamous relationship with a partner who has been tested and is known to be uninfected.

Latex male condoms, when used consistently and correctly, can reduce the risk of transmission of chlamydia.

CDC recommends yearly chlamydia testing of all sexually active women age 25 or younger, older women with risk factors for chlamydial infections (those who have a new sex partner or multiple sex partners), and all pregnant women. An appropriate sexual risk assessment by a health care provider should always be conducted and may indicate more frequent screening for some women.

Any genital symptoms such as an unusual sore, discharge with odor, burning during urination, or bleeding between menstrual cycles could mean an STD infection. If a woman has any of these symptoms, she should stop having sex and consult a health care provider immediately. Treating STDs early can prevent PID. Women who are told they have an STD and are treated for it should notify all of their recent sex partners (sex partners within the preceding 60 days) so they can see a health care provider and be evaluated for STDs. Sexual activity should not resume until all sex partners have been examined and, if necessary, treated.

Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose.

For more Information You may contact:
Division of STD Prevention (DSTDP)
Centers for Disease Control and Prevention
www.cdc.gov/std

Order Publication Online at www.cdc.gov/std/pubs

CDC-INFO Contact Center
1-800-CDC-INFO (1-800-232-4636)
Email: cdcinfo@cdc.gov

CDC National Prevention Information Network (NPIN)
P.O. Box 6003
Rockville, MD 20849-6003
1-800-458-5231
1-888-282-7681 Fax
1-800-243-7012 TTY
E-mail: info@cdcnpin.org

American Social Health Association (ASHA)
P.O. Box 13827
Research Triangle Park, NC 27709-3827
1-800-783-987

Resources:
http://www.asplandsmedicalcentre.co.uk/t11013.html
http://www.cdc.gov/std/chlamydia/STDFact-Chlamydia.htm#WhatIs
http://www.herbnews.org/chlamydiadone.htm

Categories
News on Health & Science

Of Glowing Proteins and Killer Viruses

This year’s Nobel prizes in physics, chemistry and medicine have a strong Japanese flavour.

As is the case with most great scientific discoveries, it all started with a bit of curiosity. In the 1960s, Osamu Shimomura wondered why crystal jellyfish gave off green pinpricks of light. Now, half a century later, Shimomura has been awarded for his curiosity with the Nobel prize in chemistry.

Shimomura was fascinated by the chemistry involved in bioluminescence and collected more than one million jellyfish from Friday Harbor in Washington State in the US in the 1960s and early 1970s. He spent the next 40 years meticulously examining the proteins that made them glow. In a crystal jellyfish’s approximately 300 photo-organs, Shimomura found a protein he named aequorin that produces blue light, which subsequently is converted to green light by green fluorescent protein, or GFP.

In the decades since Shimomura isolated it, GFP has revolutionised stem cell research, cloning, organ transplants, neuroscience — and everything in between. That’s because GFP can be attached biochemically to proteins within a cell, making a formerly invisible protein fluoresce beneath blue light. Proteins are extremely small and cannot be seen, even under an electron microscope. But attaching GFP makes a protein fluoresce: it’s like seeing headlights from the window of a plane even if you’re too high to make out the cars.

Proteins in human cancer cells have been tagged with GFP, and the resulting fluorescent tumours have been implanted in mice. As cancer cells break from the tumour and begin to metastasise, or move about the body, they continue to fluoresce, and scientists can watch the cancer spread.

Four other scientists are largely responsible for making this curious glowing protein into the most useful modern imaging technique available. Douglas Prasher cloned the GFP gene and was the first to think about using GFP as a fluorescent protein tag. Sergey Lukyanov won the race to find the first red fluorescent proteins, which he found in corals in a Moscow aquarium, and his research led to the discovery of fluorescent proteins in many other marine organisms.

Unfortunately, the Nobel can be shared among only three people, and these two worthy scientists were denied a slice of the $1.4 million prize.

Two others, however, join Shimomura as the new chemistry laureates: Marty Chalfie, who was the first to use GFP to light up bacteria and worms, and Roger Tsien, who has been in the forefront of fluorescent protein research since 1994 and has created a series of fluorescent proteins whose colours span the spectrum.

Many more continue to contribute to GFP research. GFP has been used to show how HIV travels from infected to non-infected cells. In another study, scientists created a mouse with fluorescent neurons that connect its whiskers with its cortex. By replacing part of its skull with a glass window, they have been able to observe how the mouse rewires its brain to cope when half of its whiskers are removed. This fluorescent window into the brain is being used to study the effects of ageing and neuro-degenerative diseases.

GFP is the microscope of the 21st century. It lets us see things we have never been able to see before. And, like the microscope, it has completely changed the way we think about science.

Green fluorescent protein has been floating in the ocean for more than 160 million years, but it took an inquisitive scientist, fascinated by bits of green light, to begin unlocking its potential.

Two French researchers were awarded the Nobel prize for medicine last week for discovering the AIDS virus, bypassing an American researcher who played a key role in the discovery.

Luc Montagnier of the World Foundation for AIDS Research and Prevention and Francoise Barre-Sinoussi of the Pasteur Institute, both in Paris, were awarded the Nobel prize in physiology and medicine by the Karolinska Institute in Stockholm for their 1983 identification of what was later named the human immunodeficiency virus (HIV).

The pair split the $1.4 million prize with Harald zur Hausen of the University of Heidelberg in Germany, who discovered that another virus, the human papilloma virus (HPV), causes cervical cancer.

Excluded from the prize was Robert C. Gallo, who for years was locked in a bitter dispute with Montagnier over credit for the discovery of HIV from work he did while at the National Cancer Institute in the US. Gallo is now at the University of Maryland.

Although the prize’s rules limit the number of scientists who can win the award to three, Jans Jornvall, scientific secretary to the assembly, made it clear the committee felt that Montagnier and Barre-Sinoussi deserved sole credit because in 1983 they published the first papers identifying the virus in the journal Science.

“We think the two that we named are the discoverers of the virus,” Jornvall said in a telephone interview. “If you look at the initial papers on the publication of the discovery you will find those who discovered it.”

Jornvall praised Gallo’s work but said the committee based its decision on the French researchers publishing their work first.

“Dr Gallo is an excellent person and has meant very much for science, but there are many people who are excellent and do very much for science,” Jornvall said. “We named the three people we consider to be the discoverers of the viruses we named.”

Other researchers said Montagnier and Barre-Sinoussi clearly deserved the prize, but that it was disappointing that Gallo was excluded.

“Gallo deserves enormous credit,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “It’s a shame you can’t give it to four people because Gallo’s contributions were enormous.”

In a written statement, Gallo congratulated the winners, adding that he was “gratified” by Montagnier’s “kind statement” that he was “equally deserving.”

“I am pleased that the Nobel Committee chose to recognise the importance of AIDS with these awards and I am proud that my colleagues and I continue to search for an AIDS vaccine,” he said.

Montagnier and Gallo were locked in a bitter dispute in the 1980s over the discovery of the virus. Beyond who should get the credit, millions of dollars were also at stake from fees for blood tests. President Ronald Reagan and French Prime Minister Jacques Chirac eventually signed an agreement in 1987 that divided the royalties equally, and Gallo and Montagnier published a paper together in The New England Journal of Medicine in 2003 acknowledging each other’s work.

In announcing the award, the Nobel Committee said Montagnier and Barre-Sinoussi’s initial discovery led to a series of crucial advances, including deciphering how the virus reproduces and infects cells and the development of the blood test and powerful antiviral drugs that have helped contain the spread of the virus and reduce the death toll.

The committee also praised zur Hausen’s work, saying he “went against current dogma” when he proposed that HPV caused cervical cancer, the second most common cancer among women and the most common sexually transmitted agent. Among other things, the work led to the development of vaccines against strains of the virus.

“The global public health burden attributable to human papilloma viruses is considerable,” the committee said.

“I’m of course totally surprised. It’s of course a great pleasure for me,” said zur Hausen, 72, said during an interview posted on the Nobel Committee’s website.

An American and two Japanese physicists won the 2008 Nobel prize in physics for their discovery of tiny asymmetries in nature’s fundamental particles that help explain why our universe exists.

Yoichiro Nambu, of the Enrico Fermi Institute at the University of Chicago, will receive half of the $1.4 million prize. The other half will be split between Makoto Kobayashi, of the High Energy Accelerator Research Organization in Tsukuba, Japan, and Toshihide Maskawa, of the Yukawa Institute for Theoretical Physics at Kyoto University.

The three physicists were pioneers in understanding “broken symmetry,” which explains why the universe can contain life as we know it. When matter and antimatter collide, they annihilate one another, leaving only radiation. In a symmetric universe with an equal amount of matter and antimatter, life — if any could exist — would be nasty, brutish and short.

That doesn’t happen because there is a tiny imbalance of one extra particle of matter for every 10 billion antimatter particles, resulting in the matter-dominated universe we live in today.

How exactly this happened is still a mystery. But Nambu, 87, born in Tokyo, was among those who opened up the field to further questions with the discovery of “spontaneous symmetry breaking”.

Nambu’s work, done in the 1960s and 1970s, predicted the behaviour of the tiny particles known as quarks and underlies the Standard Model of the universe, which unites three of the four fundamental forces of nature: the strong nuclear force, weak nuclear force and electromagnetic force. The working of gravity, and how it relates to the other three forces, is still a mystery.

Kobayashi and Maskawa predicted there were three families of quarks, instead of the two then known. Their calculations were confirmed by experiments in high-energy physics, leading to the discovery of the six quarks known today. Quarks and leptons are considered to be the two basic components of all matter, which make up atomic particles like protons and neutrons.

“It is my great honour and I can’t believe this,” Kobayashi told Reuters news service.

Physicists are now searching for spontaneous broken symmetry in the Higgs mechanism, which threw the universe into imbalance at the time of the Big Bang 13.7 billion years ago.

Scientists at the Large Hadron Collider at the European Organization for Nuclear Research, or CERN, in Switzerland will be looking for the Higgs particle when they restart the collider in spring 2009.

Sources:
The Telegraph (Kolkata, India)

Reblog this post [with Zemanta]
css.php